Latest updates on T-cell therapies for non-Hodgkin lymphoma

Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such as the TRANSCEND-OUTREACH-007 and ZUMA-12 studies successfully advancing into later phases. Although there are currently various approaches to NHL treatment, primarily employing chemotherapy, steroid medication and allogeneic stem cell transplantation, such approaches are not tolerated by all patients and may not achieve complete remissions, creating an opening for immunotherapies to address these challenges. Given the recent FDA approvals of chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel and lisocabtagene maraleucel, much attention has now turned to the potential of these novel cellular therapies for more effective treatment of NHL.

In this podcast, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Sattva Neelapu of the University of Texas MD Anderson Cancer Center, Houston, TX, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Barbara Savoldo of the University of North Carolina at Chapel Hill, Chapel Hill, NC, Max Mamonkin of the Baylor College of Medicine, Houston, TX, and Susan Prockop of the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest clinical updates on T-cell therapies for NHL, highlighting therapies such as lisocabtagene maraleucel and axicabtagene ciloleucel.

The post Latest updates on T-cell therapies for non-Hodgkin lymphoma appeared first on VJHemOnc.